The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy
Heart failure (HF) is a global public health threat affecting 26 million individuals worldwide with an estimated prevalence increase of 46% by 2030. One of the main causes of HF and sudden death in children and adult is Dilated Cardiomyopathy (DCM). DCM is characterized by dilation and systolic dysf...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-04-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.613295/full |
| _version_ | 1818412499490308096 |
|---|---|
| author | Ayat Kadhi Fathima Mohammed Georges Nemer Georges Nemer |
| author_facet | Ayat Kadhi Fathima Mohammed Georges Nemer Georges Nemer |
| author_sort | Ayat Kadhi |
| collection | DOAJ |
| description | Heart failure (HF) is a global public health threat affecting 26 million individuals worldwide with an estimated prevalence increase of 46% by 2030. One of the main causes of HF and sudden death in children and adult is Dilated Cardiomyopathy (DCM). DCM is characterized by dilation and systolic dysfunction of one or both ventricles. It has an underlying genetic basis or can develop subsequent to various etiologies that cause myocardium inflammation (secondary causes). The morbidity and mortality rates of DCM remains high despite recent advancement to manage the disease. New insights have been dedicated to better understand the pathogenesis of DCM in respect to genetic and inflammatory basis by linking the two entities together. This cognizance in the field of cardiology might have an innovative approach to manage DCM through targeted treatment directed to the causative etiology. The following review summarizes the genetical and inflammatory causes underlying DCM and the pathways of the novel precision-medicine-based immunomodulatory strategies to salvage and prevent the associated heart failure linked to the disease. |
| first_indexed | 2024-12-14T10:48:17Z |
| format | Article |
| id | doaj.art-4aed7634d8524fec8197c57ca7b17f50 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-14T10:48:17Z |
| publishDate | 2021-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-4aed7634d8524fec8197c57ca7b17f502022-12-21T23:05:21ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-04-01810.3389/fcvm.2021.613295613295The Genetic Pathways Underlying Immunotherapy in Dilated CardiomyopathyAyat Kadhi0Fathima Mohammed1Georges Nemer2Georges Nemer3Division of Genomics and Translational Biomedicine, College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, QatarDivision of Genomics and Translational Biomedicine, College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, QatarDivision of Genomics and Translational Biomedicine, College of Health and Life Sciences, Hamad Bin Khalifa University, Doha, QatarDepartment of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, LebanonHeart failure (HF) is a global public health threat affecting 26 million individuals worldwide with an estimated prevalence increase of 46% by 2030. One of the main causes of HF and sudden death in children and adult is Dilated Cardiomyopathy (DCM). DCM is characterized by dilation and systolic dysfunction of one or both ventricles. It has an underlying genetic basis or can develop subsequent to various etiologies that cause myocardium inflammation (secondary causes). The morbidity and mortality rates of DCM remains high despite recent advancement to manage the disease. New insights have been dedicated to better understand the pathogenesis of DCM in respect to genetic and inflammatory basis by linking the two entities together. This cognizance in the field of cardiology might have an innovative approach to manage DCM through targeted treatment directed to the causative etiology. The following review summarizes the genetical and inflammatory causes underlying DCM and the pathways of the novel precision-medicine-based immunomodulatory strategies to salvage and prevent the associated heart failure linked to the disease.https://www.frontiersin.org/articles/10.3389/fcvm.2021.613295/fulldilated cardiomyopathyimmunomodilationgrowth factorsprecision medicineimmuno suppression |
| spellingShingle | Ayat Kadhi Fathima Mohammed Georges Nemer Georges Nemer The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy Frontiers in Cardiovascular Medicine dilated cardiomyopathy immunomodilation growth factors precision medicine immuno suppression |
| title | The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy |
| title_full | The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy |
| title_fullStr | The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy |
| title_full_unstemmed | The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy |
| title_short | The Genetic Pathways Underlying Immunotherapy in Dilated Cardiomyopathy |
| title_sort | genetic pathways underlying immunotherapy in dilated cardiomyopathy |
| topic | dilated cardiomyopathy immunomodilation growth factors precision medicine immuno suppression |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.613295/full |
| work_keys_str_mv | AT ayatkadhi thegeneticpathwaysunderlyingimmunotherapyindilatedcardiomyopathy AT fathimamohammed thegeneticpathwaysunderlyingimmunotherapyindilatedcardiomyopathy AT georgesnemer thegeneticpathwaysunderlyingimmunotherapyindilatedcardiomyopathy AT georgesnemer thegeneticpathwaysunderlyingimmunotherapyindilatedcardiomyopathy AT ayatkadhi geneticpathwaysunderlyingimmunotherapyindilatedcardiomyopathy AT fathimamohammed geneticpathwaysunderlyingimmunotherapyindilatedcardiomyopathy AT georgesnemer geneticpathwaysunderlyingimmunotherapyindilatedcardiomyopathy AT georgesnemer geneticpathwaysunderlyingimmunotherapyindilatedcardiomyopathy |